Previous experiments showed that peptides corresponding to a major CD4-binding site on the β2 domain of MHC class II molecules, IAβ134-148, enhance responses by CD4 ⍣ T lymphocytes to antigen, allo-antigen and bacterial superantigen in vitro, and to soluble protein in vivo. To determine whether peptide IAβ134-148 acted by inhibiting antigen-induced T cell tolerance, ovalbumin-specific CD4 ⍣ lymph node (LN) T cells from TCR transgenic DO.11.10 mice were adoptively transferred into H-2 syngeneic BALB/c recipients. Tolerance was then induced by injecting antigen i.v. When peptide IAβ134-148 was used to interfere with CD4-MHC class II interactions, accumulation of clonotype-positive T lymphocytes in the LN and induction of T cell tolerance in vivo were delayed. The mechanism by which peptide IAβ134-148 inhibited T cell tolerance included the peptide's ability to block activation-induced cell death. Further, antigenspecific splenic T lymphocytes were not tolerized in IAβ134-148-treated mice, providing a reservoir of T cells that could respond to a secondary immunization. The results reported here suggest that participation of the T cell co-receptor, CD4, in TCR signaling differentially affected both T cell migration and the induction of antigen-specific tolerance. Therefore, in this in vivo model system, the combined strength of all signals received (e.g. via TCR, co-receptors and co-stimulators) determined whether T cell immunity or apoptosis and tolerance resulted from antigenic stimulation. These findings are potentially important for the development of reagents to enhance vaccine efficacy and tumor immunity.
Introduction
CD4 is a T cell co-receptor that interacts with the same MHC class II molecule recognized by the TCR (1) . Peptides corresponding to the CD4-interacting region on the β2 domain of MHC class II molecules (2) enhance T cellmediated immune responses against soluble keyhole limpet hemocyanin (KLH) administered i.p. (3) . This enhancing effect of peptide IAβ134-148 is more pronounced in mice immunized with large doses of soluble KLH (250 µg injected i.p.) than in those given small doses (10 µg i.p.). The latter suggests that IAβ134-148 may prevent tolerance induced by antigen, thereby promoting immune responses to the antigen. Additionally, IAβ134-148 induces a shift to T h 1 responses in BALB/c mice (3) .
Proliferation of activated lymphocytes is tightly regulated to prevent deleterious effects of high lymphokine concentrations and to limit tissue inflammation. Homoeostasis in the immune system may be achieved by activation-induced cell death (AICD), a mechanism leading to deletion of peripheral T lymphocytes after activation by TCR engagement (4).
Thus, systemic administration of soluble antigenic peptides or proteins may hyperstimulate antigen-specific T cells, leading to clonal exhaustion (5) and/or anergy (6) . Although effectively limiting inflammatory responses, this mechanism would also hamper efforts to induce protective T cell immunity against soluble antigen. Because reducing or altering the signal transmitted via TCR-CD4 complexes may prevent AICD, we initiated experiments to determine whether CD4-MHC class II interactions contribute to development of activation-induced, antigen-specific T cell tolerance.
Tolerance can be induced in transgenic mice expressing a single TCR only after decreasing the numbers of CD4 ϩ T cells (7) . However, when T lymphocytes from TCR transgenic mice are transferred into normal syngeneic mice, tolerance can be achieved by systemically administered soluble antigen (8) . We therefore transferred into BALB/c mice naive CD4 ϩ lymph node (LN) T cells expressing the DO.11.10 TCR, which is specific for peptide 323-339 from chicken ovalbumin (OVA323-339) (9) . Following the procedure of Kearney et al. (8) , we tolerized adoptive transfer recipients to OVA323-339. When the mice were treated with peptide IAβ134-148 to interfere with CD4-MHC class II interactions, AICD was inhibited, the onset of tolerance in LN T cells delayed and splenic T cells not tolerized. These findings may aid in the rational design of reagents to improve vaccine efficacy and tumor immunity.
Methods

Mice
BALB/c mice were purchased from Harlan Sprague-Dawley (Houston, TX). Founding pairs for the DO.11.10 TCR transgenic mice (9) were generously provided by Dr D. Y. Loh (Nippon Roche Research Center, Kanagawa, Japan) and bred to normal BALB/c mice in the UTMB animal facility according to National Institutes of Health guidelines. Expression of the TCR transgene was screened by two-color flow cytometric analysis of erythrocyte-depleted peripheral blood lymphocytes stained with anti-mouse CD4 mAb GK1.5 and anti-DO.11.10 TCR mAb KJ1-26.1 (10) .
Media and cell lines
DMEM containing 5% heat-inactivated FCS, 2 mM L-glutamine, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 10 mM HEPES and 50 µM 2-mercaptoethanol was used for all cell culture experiments with mouse lymphocytes. This medium is henceforth called D5. The hybridoma line KJ1-26.1 (10) was a generous gift of Dr J. Kappler and Dr. P. Marrack (Howard Hughes Medical Institute, Denver, CO), and was cultured in RPMI 1640 containing 10% FCS and all supplements. The anti-mouse CD4 hybridoma, GK1.5, and the cytokine-dependent indicator cell lines, CTLL-2 and FD.C/ 1, were obtained from the American Type Culture Collection (Rockville, MD) and cultured according to their recommendations.
Purification of mAb and FITC conjugation
mAb KJ1-26.1 directed against the DO.11.10 TCR clonotype was purified from hybridoma supernatants by affinity chromatography on Sepharose G (Sigma, St Louis, MO) as described (11) . The IgG fraction was eluted from the column with 0.15 M sodium chloride in 0.05 M glycine, pH 2.3. FITC was conjugated by incubating 1.2 mg of IgG and 2.4 mg of FITC (Sigma) at 4°C for 14 h (12).
Peptides
Peptides were synthesized in the Protein Chemistry Laboratory of the Sealy Center for Molecular Science at UTMB (3).
Preparation of LN T cells, adoptive transfer, tolerization and immunization
Cells from the axillary, brachial, cervical, inguinal, popliteal and mesenteric LN of DO.11.10 TCR transgenic mice were enriched for the expression of the CD4 co-receptor by antibody-mediated depletion of CD8 ϩ and class II MHC ϩ cells (3) . BALB/c mice were injected via the tail vein with 3.5ϫ10 6 T cells without (groups 1 and 2) or with 250 µg of peptide IAβ134-148 (group 3). After 4 h, mice in groups 1 and 3 received 250 µg OVA323-339 by i.v. tail injection. Mice in group 3 were injected daily, but not Ͼ5 times, i.p. with 250 µg of IAβ134-148 plus 250 µg of IAβC134-148PGPC, a structurally constrained form of the peptide (3). Mice in group 1 received an equal volume of PBS. To immunize adoptive transfer recipients, 12 days after transferring the T cells, mice were injected s.c. at three sites in the back with 300 µg of OVA323-339 in 100 µl PBS:complete Freund's adjuvant (CFA) (1:1, v/v).
In vitro stimulation with antigen
At various times after transferring the lymphocytes, cell suspensions were prepared from LN (axillary, brachial, cervical, inguinal, popliteal and mesenteric) and spleens of recipient mice (3) . Only the draining LN (axillary, brachial, inguinal and popliteal) from mice injected s.c. with antigen in CFA were used. LN T cells were re-stimulated in the wells of a flatbottom 96-well plate by culturing 4ϫ10 5 LN cells/well with 8ϫ10 5 irradiated splenocytes from normal BALB/c mice and various concentrations of OVA323-339. Splenocytes from adoptive transfer recipients were cultured at 8ϫ10 5 cells/well without irradiated feeder cells. Lymphocyte proliferation was determined in triplicate cultures by [ 3 H]thymidine incorporation during the last 18 h of a 90 h incubation (3). Concentrations of IL-2 and IL-3 in culture supernatants were measured after 48 h of incubation as described (3) .
Long-term cultures were initiated with 5-10ϫ10 6 LN cells or 10-20ϫ10 6 splenocytes per well with or without rIL-2 (10 U/ml) in 24-well plates. Cells were incubated with 10 µM OVA323-339 for 3 days, washed 3 times with D5 and replated with irradiated BALB/c splenocytes (8ϫ10 6 cells/ well). The cultures were then incubated without antigen and with 10 U/ml of rIL-2 or without rIL-2. After 10 days, surviving lymphocytes were harvested and incubated in 96-well plates at 0.5-2ϫ10 5 cells/well with 4ϫ10 5 irradiated BALB/c splenocytes and various concentrations of OVA323-339. Cell proliferation and cytokine production were determined as described above.
Specific cell death
LN cells (4ϫ10 5 /well) were incubated with or without 40 µM OVA323-339 for 2 days. Viable and dead cells in each well were counted after Trypan blue staining. The percentage of dead cells was determined as the ratio of Trypan blue-stained cells versus total number of cells. Antigen-specific cell death was calculated as described (13) 
Flow cytometry
LN and spleens were dissected from adoptive transfer recipients. Cell suspensions were prepared (3), and washed with PBS containing 2% FCS and 0.02% sodium azide. Samples were adjusted to 1ϫ10 6 cells in 100 µl and incubated on ice for 5 min with 1 µg of anti-mouse CD32/CD16 (mAb 2.4G2; PharMingen, San Diego, CA) to block FcγII and FcγIII receptors. The samples were then stained with FITC-conjugated KJ1-26.1, R-phycoerythrin (R-PE)-conjugated anti-mouse CD11a (mAb I21/7; Caltag, Burlingame, CA) or biotinylated anti-mouse CD62L (mAb MEL-14; Caltag) followed by streptavidin-R-PE (Caltag). Surface expression of DO.11.10 TCR, LFA-1 and CD62L (L-selectin) were determined by one or two-color flow cytometry on a FACScan. Acquired data were analyzed with the CellQuest program.
Results
Peptides corresponding to CD4-interacting regions on MHC class II delay antigen-induced T cell tolerance
We have previously demonstrated that peptide IAβ134-148 binds directly to CD4 ϩ T cells and modulates T cell-mediated immune responses in vitro and in vivo (3) . BALB/c mice treated i.p. with IAβ134-148, but not mice treated with control peptides, respond more vigorously to immunization with soluble KLH. Also, the KLH-specific T cells from IAβ134-148-treated mice display a more prominent T h 1 phenotype (3). A potential mechanism for this effect is inhibition of antigen-specific T cell tolerance.
To test whether T cell tolerance to antigenic peptides can be prevented by interfering with the signal transmitted via TCR-CD4 complexes without reducing the antigen concentration, we adoptively transferred a defined number of CD4 ϩ LN T cells from mice transgenic for the DO.11.10 TCR into normal mice with identical H-2 background (BALB/c). The mice were then injected i.v. with 300 µg of OVA323-339 (group 1) to induce tolerance (8) or with PBS (group 2). A third group of mice received DO.11.10 TCR ϩ CD4 ϩ T cells and 250 µg of peptide IAβ134-148 4 h before being injected with the tolerogenic dose of OVA323-339, and five daily i.p. injections with IAβ134-148. After 6 days, we re-stimulated LN cell preparations from individual mice in vitro with OVA323-339 and determined the OVA-specific T cell responses ( Fig. 1) . Lymphocytes from unprimed recipients of DO.11.10 TCR ϩ T cells proliferated in an antigen dose-dependent fashion, whereas lymphocytes from recipient mice injected with a tolerogenic dose of OVA323-339 responded poorly to restimulation in vitro, requiring at least 100 times more peptide for equivalent responses. However, lymphocytes from mice that received both IAβ134-148 and a tolerogenic dose of OVA323-339 proliferated more vigorously than unprimed lymphocytes. Secretion of IL-2 into the culture medium paralleled the proliferation data (not shown). Similar results were obtained when LN T cells were analyzed 8 days after the adoptive transfer. These results suggested that peptide IAβ134-148 may interfere with a signal via TCR-CD4 complexes, either by competitively inhibiting interactions between CD4 and MHC class II molecules, or by affecting the signal transduction machinery prior to the cells' encounter with antigen. This interference with participation of CD4 in signal transduction during antigen-specific T cell stimulation could have prevented or delayed T cell tolerance. Two potential mechanisms leading to T cell tolerance in this adoptive transfer system are activation-induced anergy and T cell death.
Tolerance induction by antigen is dependent upon prolonged exposure of T lymphocytes to antigen
Because at 6 days post-treatment, the LN of OVA323-339-treated mice still contained KJ1-26.1 ϩ T cells (see legend to Fig. 1 ), the observed tolerant state could not have been due solely to clonal exhaustion. To test whether the cause for tolerance in our system was clonal anergy, we analyzed LN T cells from adoptive transfer recipients 40 or 66 h posttransfer instead of 6 days post-transfer. At 40 h, we detected activated KJ1-26.1 ϩ T lymphocytes in the LN of mice given a tolerogenic dose of antigen (Fig. 2B) . Both LN from OVA323-339-injected and from non-primed animals contained KJ1-26.1 ϩ T lymphocytes. However, only in the primed mice did the KJ1-26.1 ϩ T cells display the phenotype of large, activated blast cells. We could not detect KJ1-26.1 ϩ T lymphocytes after 40 h in the LN of mice treated with IAβ134-148 before application of the tolerogen (Fig. 2D) . Consequently, LN cells recovered from IAβ134-148-treated recipients after this time failed to proliferate following in vitro stimulation with OVA323-339, whereas T lymphocytes from mice injected only with OVA323-339 and from unprimed mice responded well to in vitro stimulation (Fig. 3A) . LN cell preparations from OVA323-339-primed and unprimed mice contained comparable relative numbers of KJ1-26.1 ϩ T cells (Table 1) . Therefore, OVA323-339-primed LN T cells incorporated more [ 3 H]thymidine per KJ1-26.1 ϩ cell than unprimed LN T cells and can be deemed hyper-responsive.
The failure of KJ1-26.1 ϩ T lymphocytes that were treated with IAβ134-148 to accumulate in the LN within 40 h after transfer was not due to inability to transplant in these experiments because KJ1-26.1 ϩ T cells were present in the spleen (Table 1) . Rather, this observation suggested a block in the ability of the transferred lymphocytes to accumulate in the LN. After 64 h, KJ1-26.1 ϩ T cells were also detectable in the LN of IAβ134-148-treated mice ( Table 1) . Estimates of cell size by forward light scatter indicated that these cells were blastic (not shown). Further, these cells responded as well as naive T cells to in vitro stimulation ( Fig. 3B and C) . At this time, the LN of OVA323-339-injected mice contained more KJ1-26.1 ϩ T cells than the LN of unprimed mice, indicating that i.v.-injected antigen stimulated cellular proliferation (Table 1) . They were, however, no longer hyperresponsive to OVA323-339. The transient hyper-responsiveness of LN T cells recovered from OVA323-339-injected mice is apparent from the comparison of relative numbers of KJ1-26.1 ϩ T cells in LN from the various groups (Table 1) , with proliferation after in vitro stimulation of the same cells (Fig. 3A and B) .
Lack of IL-2 production is one of the hallmarks of anergy (6). Lymphocytes from OVA323-339-injected mice, however, were also hyper-responsive with regard to IL-2 production when re-stimulated after 36 h (not shown). For at least 60 h after injection with OVA323-339, transferred T cells recovered from the LN or the spleen responded to in vitro stimulation with IL-2 production (Figs 3C and 4B) . Further, LN and splenic T cells recovered from transfer recipients 36 or 60 h after i.v. injection of a tolerogenic dose of OVA323-339 could be maintained in culture and proliferated upon secondary restimulation with OVA323-339. These T cells also secreted IL-2 and IL-3 upon re-stimulation in culture (Fig. 5 ). However, 6 or 8 days after the adoptive transfer, only LN T cells recovered from mice not injected with OVA323-339 or treated with IAβ134-148 before i.v. injection of OVA323-339 could be maintained in culture and induced to respond to antigen re-stimulation (data not shown). Therefore, if anergy was induced in these experiments, non-responsiveness to antigen re-stimulation did not immediately follow the initial encounter with ovalbumin but depended on prolonged exposure to the antigen.
Peptides corresponding to CD4-interacting regions on MHC class II prevent antigen-induced T cell death
Injection of OVA323-339 via the tail vein resulted in cellular proliferation of transferred clonotype-positive T lymphocytes (Table 1) . Six days thereafter, however, the percentage of clonotype-positive cells in LN of OVA323-339-injected recipients was reduced when compared to control recipients (see legend to Fig. 1 ), suggesting that initial clonal expansion was followed by clonal exhaustion or T cell death. Detection of late-stage apoptotic cells in the LN of adoptive transfer recipients proved difficult (8, data not shown and Fig. 6A ), presumably because apoptotic cells are rapidly cleared from the LN and the circulation (15) . However, we observed repeatedly clonotype-positive cells with subdiploid DNA content in LN recovered from recipients treated with OVA323-339, but not in LN from recipients that had additionally received IAβ134-148. This observation indicated the presence of T cells in the early stages of apoptosis (Fig. 6A) . To determine whether IAβ134-148-treatment may have inhibited antigen-induced T cell death, we therefore re-stimulated LN cells from adoptive transfer recipients with OVA323-339 in vitro Mice that were analyzed after 22 days were additionally injected s.c. with 300 µg of OVA323-339 emulsified in CFA on day 12. After the indicated times, LN and spleens were removed from transfer recipients, and cells were stained with FITC-KJ1-26.1 (anti-clonotype mAb). Live cells were gated on forward and side light scatter, and fluorescence data on 50,000 viable cells were collected using a 4-decade logarithmic amplification. Data shown are from individual experiments and are expressed as mean Ϯ SD of three mice per treatment. In each experiment, LN cells and splenocytes of a control mouse that did not receive CD4 ϩ KJ1-26.1 ϩ LN T cells were included to determine background staining. Background staining was 0.16 Ϯ 0.03% (mean Ϯ SD for depicted experiments) for LN T cells. For splenocytes, the background was 0.4 Ϯ 0.1% in 36 and 60 h experiments, and 2.2% in the 22 day experiment shown. Statistical analysis using Student's unpaired t-test yielded for LN at 36 h P Ͻ 0.005 (G1 versus G3 and G2 versus G3); for LN at 60 h P Ͻ 0.001 (G1 versus G2), P Ͻ 0.05 (G2 versus G3); for LN at 22 d P Ͻ 0.05 (G1 versus G2 and G2 versus G3); for spleen at 36 h P Ͻ 0.005 (G1 versus G2 and G2 versus G3), P Ͻ 0.05 (G1 versus G3); for spleen at 60 h P Ͻ 0.001 (G1 versus G2), P Ͻ 0.01 (G2 versus G3); for spleen at 22 d P Ͻ 0.05 (G1 versus G2, G1 versus G3 and G2 versus G3). An asterisk indicates that the marked value significantly differs from the corresponding value under G1 (OVA323-339 i.v. injected group).
and measured the percentage of antigen-induced cell death (Fig. 6B) . After 2 days, more dead cells were detected in antigen-re-stimulated cultures of LN cells from OVA323-339-primed adoptive transfer recipients than in control cultures without antigen. In contrast, LN cell cultures from either unprimed or primed and IAβ134-148-treated recipients were protected from antigen-induced cell death. The percentage of viable and dead cells did not differ between cell cultures in the absence of antigen. The LN cell cultures started with 3.3 and 4.7% of clonotype-positive T cells for OVA323-339-primed and primed plus IAβ134-148-treated recipients respectively. Therefore, the observed difference in antigenspecific lysis between primed (ϩ5%) and primed plus IAβ134-148-treated LN T cells (-5%) suggests a substantial protective effect of peptide IAβ134-148.
To establish whether primary exposure to OVA323-339 could induce apoptosis in KJ1-26.1 ϩ T lymphocytes and whether treatment with IAβ134-148 inhibited activationinduced apoptosis, we stimulated LN cells from DO.11.10 TCR transgenic mice in vitro with antigen-pulsed irradiated splenocytes from BALB/c mice. We then stained the cultured cells with the clonotypic mAb and measured DNA contents by PI staining (Fig. 7) . KJ1-26.1 ϩ T cells that were incubated for only 3 h with OVA323-339 were diploid, whereas after 48 h, a large percentage of KJ1-26.1 ϩ T cells were subdiploid, an indication that they were undergoing apoptosis. LN cell cultures incubated with IAβ134-148 before adding antigenpulsed splenocytes contained fewer KJ1-26.1 ϩ apoptotic cells after 48 h. Treatment with IAβ134-148 had no effect on DNA content after 3 h or in the absence of antigen (not shown). These results demonstrate that IAβ134-148 present during challenge with high doses of antigen inhibited apoptosis and suggest that CD4-MHC class II interactions may participate in mediating antigen-induced T cell death.
Soluble peptide antigen tolerizes LN T cells but not splenic T cells
To determine whether delayed accumulation of KJ1-26.1 ϩ T cells in LN in IAβ134-148-treated mice merely postponed or permanently prevented antigen-induced T cell tolerance, we immunized adoptive transfer recipients 12 days post-transfer by s.c. injection of OVA323-339 emulsified in CFA. Ten days later, we re-stimulated LN cells and splenocytes in vitro with various concentrations of OVA323-339. In cultures of LN T cells from transfer recipients that received an i.v. injection of OVA323-339, proliferative responses (Fig. 8 ) and IL-2 production (data not shown) were weak, and did not differ whether the mice were treated with IAβ134-148 or not. LN T cells from mice that were exposed to OVA323-339 in adjuvant, but not in soluble form, responded vigorously to re-stimulation in vitro. Splenocytes from IAβ134-148-treated mice given an i.v. injection of OVA323-339 responded more vigorously than those from either the tolerized or the untolerized groups. Therefore, KJ1-26.1 ϩ T cells residing in the spleen of IAβ134-148-treated mice were not tolerized. However, KJ1-26.1 ϩ T cells were deleted from the LN in mice that were exposed to OVA323-339 under tolerizing conditions whether the mice were IAβ134-148 treated or not.
Discussion
Our findings suggest that systemic administration of soluble antigen induced T cell tolerance by repetitive signaling via TCR-CD4 complexes resulting in AICD. Although transferred KJ1-26.1 ϩ T cells were activated by soluble OVA323-339 and migrated to the LN in our system (Fig. 2) , they were eventually tolerized (Fig. 1) . Tolerance occurred despite the presence of antigen-presenting cells (APC) capable of co-stimulation in the T cell-rich paracortex of the LN (16) . Treatment of T lymphocytes with IAβ134-148 before exposure to OVA323-339 delayed migration of transferred KJ1-26.1 ϩ T cells into LN and onset of antigen-specific T cell tolerance. Treated KJ1-26.1 ϩ LN T cells remained phenotypically naive with respect to expression of CD62L, TCR and LFA-1 (not shown) for at least 60 h after OVA323-339 injection. Our results, however, cannot be explained by inhibition of signaling via the TCR by IAβ134-148, because clonotype-positive cells expanded in the spleens of the mice after OVA323-339 injection (Table 1) , and their splenic T cells were hyperresponsive after in vitro re-stimulation (Fig. 4) and s.c. immunization (Fig. 8) . Additional evidence comes from the observation that in vitro, IAβ134-148 inhibited AICD in previously unstimulated KJ1-26.1 ϩ LN T cells (Fig. 7) , but enhanced cytokine secretion and proliferation under the same conditions (3).
More likely, the mechanism by which IAβ134-148 inhibited tolerance in KJ1-26.1 ϩ T cells was a delay in the accumulation of transferred T cells in the LN and, therefore, a reduced exposure to antigen presented by APC in the paracortex. Ingulli et al. (16) , using the same adoptive transfer system, showed that antigen-pulsed dendritic cells home to the paracortical regions of the LN, where they interact with antigenspecific T cells. Our data demonstrate that participation of CD4 in TCR signaling may regulate T cell accumulation in LN. Exposure to IAβ134-148, therefore, protected KJ1-26.1 ϩ T lymphocytes from antigen-induced tolerance in a 2-fold manner. Firstly, AICD was directly prevented (Figs 6 and 7) and, secondly, accumulation of transferred KJ1-26.1 ϩ T cells in LN was delayed, thereby reducing initial exposure to antigen (Fig. 2) . In our system, only LN T cells, but not splenic T cells, were tolerized by soluble, systemically administered antigen (Fig. 8) . The prolonged interaction between antigenpulsed dendritic cells and KJ1-26. CD4 complexes resulted in functional tolerance are observations that activated mature T cells are sensitive to AICD upon secondary encounters with antigen (18, 19) . Also, several studies examining protection by CD28-mediated co-stimulation of activated T lymphocytes from apoptosis after TCR religation have yielded contradictory results (20, 21) . On the one hand, cross-linking CD28 on the surface of activated T cells via anti-CD28 mAb and secondary anti-IgG antibody was reported to protect from TCR-mediated apoptosis (21, 22) . On the other hand, Boehme and colleagues observed no protective effects of CD28 co-stimulation (20). Boehme's experimental conditions may have more closely simulated physiological parameters because he used concentrations of soluble anti-CD28 mAb that would have provided optimal costimulation for T cell activation. In addition, the chimeric protein, CTLA-4-Ig, which blocks co-stimulation via CD28 by binding to the CD28 ligands B7-1 and B7-2 (23), decreases antigen-induced proliferation of T cells in the presence of splenic APC by Ͼ70%, but does not enhance cell death of activated T cells upon re-stimulation with antigen and splenic APC (20) . Lastly, activated LN T cells from CD28-deficient mice and wild-type mice do not differ in the extent of AICD (20) . Our results suggest differential signaling in the presence or the absence of interactions between CD4 and MHC class II molecules during TCR activation. Importantly, Combadiere et al. demonstrated that individual immunoreceptor tyrosinebased activation motifs (ITAM) play unique roles in TCR responses by engaging specific signaling pathways (24) . Antagonist peptide ligands that cause anergy in responding mature T cells activate a subset of available ITAM and induce different signaling pathways than do agonist peptides (25, 26) . Further, partial agonists, which induce a subset of T cell The significance of differences was tested using the unpaired Student's t-test. (A) P Ͻ 0.001 for groups 1 and 3 compared to group 2. (B) P Ͻ 0.001 for groups 2 and 3 compared to group 1, and P Ͻ 0.07 for group 3 compared to group 2. Independent repetitions of this experiment using OVA323-339 at 0.04-10 µM yielded similar results. signals, can be converted into TCR antagonists by anti-CD4 mAb (27) . To explain the ability of ligands with different affinities for the TCR to elicit qualitatively different signals, a kinetic proofreading model postulates that the temporal pattern of interactions between MHC-peptide ligands and the TCR in combination with TCR occupancy determines the T cell response (28) . Thus, low concentrations of high-affinity peptide-MHC ligands will induce a full complement of T cell signaling events leading to cytokine production and cellular proliferation, whereas higher concentrations of low-affinity peptide-MHC ligands will not, even if comparable numbers of TCR-peptide-MHC complexes were achieved (28) .
Interactions between the T cell co-receptor, CD4, and MHC class II molecules are an integral part of the initial signal transduction complex and provide stability to the TCRpeptide-MHC interaction, converting a low-affinity ligand into a TCR agonist. However, increased or repetitive signaling beyond an upper threshold leading to T cell death and clonal exhaustion could be achieved by high concentrations of high-affinity TCR ligands. For example, when transgenic mice expressing a TCR specific for the N-terminal peptide of myelin basic protein are injected i.v. with soluble peptide antigen or analogs that bind with increasing affinity to the restricting MHC class II, I-A u , AICD occurs in peripheral T cells (29) . The degree of apoptosis directly correlates with the peptides' affinity for I-A u . Thus, reduced stability of TCR-CD4 and peptide-MHC class II complexes by interference with CD4-MHC class II interactions could modulate signal transduction pathways and prevent T cell death in our system. The importance of CD4-MHC class II interactions for the differentiation of CD4 ϩ T cells has recently been demonstrated by Fowell et al., who found that APC that express mutant MHC class II molecules unable to interact with CD4 cannot induce differentiation to the T h 2 type (30).
CD4-MHC class II interactions may control deletion pathways and contribute to regulating peripheral T cell tolerance in a manner similar to other interactions between costimulators/co-receptors and their ligands. For example, engagement of CD2 by anti-CD2 mAb decreases CD3-mediated AICD in a T cell hybridoma line and a T h cell clone (31) . The mechanism by which CD2-stimulation inhibits apoptosis includes blocking CD3-induced up-regulation of Fas and FasL.
Our findings have important implications for the development of vaccines capable of inducing protective T cell immunity. For example, it may be possible to manipulate T h 1/T h 2 ratios by affecting the degree of CD4-MHC class II interactions during antigenic stimulation. Future experiments need to address the question whether the fate of antigen-specific T cell populations is determined by the integrated strength and duration of all signals received (e.g. via TCR, co-receptors, co-stimulators and growth factor receptors) or by a balance between signals via TCR-CD4 complexes and co-stimulator molecules.
